Clinical benefit from erythropoietin

Mario Dicato*, Caroline Duhem, Guy Berchem, Fernand Ries

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

19 Citations (Scopus)

Abstract

Advances continue in erythropoietin biology, and additional data reviewed here have recently become available on complex feedback mechanisms describing the interrelations of hypoxia and its effects on anemia and tumor behavior (eg, apoptosis, angiogenesis). In addition to biology, other clinically relevant data in oncology are included and an attempt is made to identify patients who are most likely to benefit from treatment. The latter aspects will better define the profile of the target patient, probably prevent overtreatment, and improve cost-benefit ratios. Interesting data on radiotherapy results improved by increasing tissue hemoglobin have been published but will need further confirmation.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalCurrent Opinion in Oncology
Volume12
Issue number4
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Dive into the research topics of 'Clinical benefit from erythropoietin'. Together they form a unique fingerprint.

Cite this